Moderna (MRNA) jumps after flu vaccine data, FDA decision looms

Moderna (MRNA) shares rose 12.3% to $54.35 on May 12, 2026, after the company reported positive clinical data for two vaccine candidates, including Phase 3 results for its seasonal flu shot. The flu vaccine candidate, mRNA-1010, showed 26.6% relative vaccine efficacy versus standard-dose flu shots in adults 50 and older, according to results published in the New England Journal of Medicine. The data could support broader investor confidence in Moderna’s mRNA platform beyond COVID-19. A U.S. Food and Drug Administration decision is expected by August 5, 2026. Moderna also said its hantavirus vaccine candidate was well-tolerated and generated strong immune responses in a Phase 1 trial. Several analysts raised price targets following the updates. The stock is up 76.6% year to date and is trading near its 52-week high of $57.80 reached in March 2026.